Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial

on behalf of the VTI-208 Study Group

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There is no proven effective treatment for sAH, which is why early transplantation has been increasingly discussed. Hepatoblastoma-derived C3A cells express anti-inflammatory proteins and growth factors and were tested in an extracorporeal cellular therapy (ELAD) study to establish their effect on survival for subjects with sAH. Adults with sAH, bilirubin ≥8 mg/dL, Maddrey's discriminant function ≥ 32, and Model for End-Stage Liver Disease (MELD) score ≤ 35 were randomized to receive standard of care (SOC) only or 3-5 days of continuous ELAD treatment plus SOC. After a minimum follow-up of 91 days, overall survival (OS) was assessed by using a Kaplan-Meier survival analysis. A total of 203 subjects were enrolled (96 ELAD and 107 SOC) at 40 sites worldwide. Comparison of baseline characteristics showed no significant differences between groups and within subgroups. There was no significant difference in serious adverse events between the 2 groups. In an analysis of the intent-to-treat population, there was no difference in OS (51.0% versus 49.5%). The study failed its primary and secondary end point in a population with sAH and with a MELD ranging from 18 to 35 and no upper age limit. In the prespecified analysis of subjects with MELD < 28 (n = 120), ELAD was associated with a trend toward higher OS at 91 days (68.6% versus 53.6%; P =.08). Regression analysis identified high creatinine and international normalized ratio, but not bilirubin, as the MELD components predicting negative outcomes with ELAD. A new trial investigating a potential benefit of ELAD in younger subjects with sufficient renal function and less severe coagulopathy has been initiated. Liver Transplantation 24 380–393 2018 AASLD.

Original languageEnglish (US)
Pages (from-to)380-393
Number of pages14
JournalLiver Transplantation
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Alcoholic Hepatitis
End Stage Liver Disease
Randomized Controlled Trials
Standard of Care
Bilirubin
Hepatoblastoma
Therapeutics
International Normalized Ratio
Kaplan-Meier Estimate
Survival Analysis
Liver Transplantation
Population
Creatinine
Intercellular Signaling Peptides and Proteins
Anti-Inflammatory Agents
Transplantation
Regression Analysis
Kidney
Proteins

ASJC Scopus subject areas

  • Surgery
  • Hepatology
  • Transplantation

Cite this

Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis : A multinational, prospective, controlled, randomized trial. / on behalf of the VTI-208 Study Group.

In: Liver Transplantation, Vol. 24, No. 3, 01.03.2018, p. 380-393.

Research output: Contribution to journalArticle

@article{0105d20582954b709ee6b63cd47423f8,
title = "Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial",
abstract = "Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There is no proven effective treatment for sAH, which is why early transplantation has been increasingly discussed. Hepatoblastoma-derived C3A cells express anti-inflammatory proteins and growth factors and were tested in an extracorporeal cellular therapy (ELAD) study to establish their effect on survival for subjects with sAH. Adults with sAH, bilirubin ≥8 mg/dL, Maddrey's discriminant function ≥ 32, and Model for End-Stage Liver Disease (MELD) score ≤ 35 were randomized to receive standard of care (SOC) only or 3-5 days of continuous ELAD treatment plus SOC. After a minimum follow-up of 91 days, overall survival (OS) was assessed by using a Kaplan-Meier survival analysis. A total of 203 subjects were enrolled (96 ELAD and 107 SOC) at 40 sites worldwide. Comparison of baseline characteristics showed no significant differences between groups and within subgroups. There was no significant difference in serious adverse events between the 2 groups. In an analysis of the intent-to-treat population, there was no difference in OS (51.0{\%} versus 49.5{\%}). The study failed its primary and secondary end point in a population with sAH and with a MELD ranging from 18 to 35 and no upper age limit. In the prespecified analysis of subjects with MELD < 28 (n = 120), ELAD was associated with a trend toward higher OS at 91 days (68.6{\%} versus 53.6{\%}; P =.08). Regression analysis identified high creatinine and international normalized ratio, but not bilirubin, as the MELD components predicting negative outcomes with ELAD. A new trial investigating a potential benefit of ELAD in younger subjects with sufficient renal function and less severe coagulopathy has been initiated. Liver Transplantation 24 380–393 2018 AASLD.",
author = "{on behalf of the VTI-208 Study Group} and Julie Thompson and Natasha Jones and Ali Al-Khafaji and Shahid Malik and David Reich and Santiago Munoz and Ross MacNicholas and Tarek Hassanein and Lewis Teperman and Lance Stein and Andr{\'e}s Duarte-Rojo and Raza Malik and Talal Adhami and Sumeet Asrani and Nikunj Shah and Paul Gaglio and Anupama Duddempudi and Brian Borg and Rajiv Jalan and Robert Brown and Heather Patton and Rohit Satoskar and Simona Rossi and Amay Parikh and Ahmed ElSharkawy and Parvez Mantry and Linda Sher and David Wolf and Marquis Hart and Charles Landis and Alan Wigg and Habib, {Shahid -} and Geoffrey McCaughan and Steven Colquhoun and Alyssa Henry and Patricia Bedard and Lee Landeen and Michael Millis and Robert Ashley and William Frank and Andrew Henry and Jan Stange and Ram Subramanian",
year = "2018",
month = "3",
day = "1",
doi = "10.1002/lt.24986",
language = "English (US)",
volume = "24",
pages = "380--393",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis

T2 - A multinational, prospective, controlled, randomized trial

AU - on behalf of the VTI-208 Study Group

AU - Thompson, Julie

AU - Jones, Natasha

AU - Al-Khafaji, Ali

AU - Malik, Shahid

AU - Reich, David

AU - Munoz, Santiago

AU - MacNicholas, Ross

AU - Hassanein, Tarek

AU - Teperman, Lewis

AU - Stein, Lance

AU - Duarte-Rojo, Andrés

AU - Malik, Raza

AU - Adhami, Talal

AU - Asrani, Sumeet

AU - Shah, Nikunj

AU - Gaglio, Paul

AU - Duddempudi, Anupama

AU - Borg, Brian

AU - Jalan, Rajiv

AU - Brown, Robert

AU - Patton, Heather

AU - Satoskar, Rohit

AU - Rossi, Simona

AU - Parikh, Amay

AU - ElSharkawy, Ahmed

AU - Mantry, Parvez

AU - Sher, Linda

AU - Wolf, David

AU - Hart, Marquis

AU - Landis, Charles

AU - Wigg, Alan

AU - Habib, Shahid -

AU - McCaughan, Geoffrey

AU - Colquhoun, Steven

AU - Henry, Alyssa

AU - Bedard, Patricia

AU - Landeen, Lee

AU - Millis, Michael

AU - Ashley, Robert

AU - Frank, William

AU - Henry, Andrew

AU - Stange, Jan

AU - Subramanian, Ram

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There is no proven effective treatment for sAH, which is why early transplantation has been increasingly discussed. Hepatoblastoma-derived C3A cells express anti-inflammatory proteins and growth factors and were tested in an extracorporeal cellular therapy (ELAD) study to establish their effect on survival for subjects with sAH. Adults with sAH, bilirubin ≥8 mg/dL, Maddrey's discriminant function ≥ 32, and Model for End-Stage Liver Disease (MELD) score ≤ 35 were randomized to receive standard of care (SOC) only or 3-5 days of continuous ELAD treatment plus SOC. After a minimum follow-up of 91 days, overall survival (OS) was assessed by using a Kaplan-Meier survival analysis. A total of 203 subjects were enrolled (96 ELAD and 107 SOC) at 40 sites worldwide. Comparison of baseline characteristics showed no significant differences between groups and within subgroups. There was no significant difference in serious adverse events between the 2 groups. In an analysis of the intent-to-treat population, there was no difference in OS (51.0% versus 49.5%). The study failed its primary and secondary end point in a population with sAH and with a MELD ranging from 18 to 35 and no upper age limit. In the prespecified analysis of subjects with MELD < 28 (n = 120), ELAD was associated with a trend toward higher OS at 91 days (68.6% versus 53.6%; P =.08). Regression analysis identified high creatinine and international normalized ratio, but not bilirubin, as the MELD components predicting negative outcomes with ELAD. A new trial investigating a potential benefit of ELAD in younger subjects with sufficient renal function and less severe coagulopathy has been initiated. Liver Transplantation 24 380–393 2018 AASLD.

AB - Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There is no proven effective treatment for sAH, which is why early transplantation has been increasingly discussed. Hepatoblastoma-derived C3A cells express anti-inflammatory proteins and growth factors and were tested in an extracorporeal cellular therapy (ELAD) study to establish their effect on survival for subjects with sAH. Adults with sAH, bilirubin ≥8 mg/dL, Maddrey's discriminant function ≥ 32, and Model for End-Stage Liver Disease (MELD) score ≤ 35 were randomized to receive standard of care (SOC) only or 3-5 days of continuous ELAD treatment plus SOC. After a minimum follow-up of 91 days, overall survival (OS) was assessed by using a Kaplan-Meier survival analysis. A total of 203 subjects were enrolled (96 ELAD and 107 SOC) at 40 sites worldwide. Comparison of baseline characteristics showed no significant differences between groups and within subgroups. There was no significant difference in serious adverse events between the 2 groups. In an analysis of the intent-to-treat population, there was no difference in OS (51.0% versus 49.5%). The study failed its primary and secondary end point in a population with sAH and with a MELD ranging from 18 to 35 and no upper age limit. In the prespecified analysis of subjects with MELD < 28 (n = 120), ELAD was associated with a trend toward higher OS at 91 days (68.6% versus 53.6%; P =.08). Regression analysis identified high creatinine and international normalized ratio, but not bilirubin, as the MELD components predicting negative outcomes with ELAD. A new trial investigating a potential benefit of ELAD in younger subjects with sufficient renal function and less severe coagulopathy has been initiated. Liver Transplantation 24 380–393 2018 AASLD.

UR - http://www.scopus.com/inward/record.url?scp=85042359887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042359887&partnerID=8YFLogxK

U2 - 10.1002/lt.24986

DO - 10.1002/lt.24986

M3 - Article

C2 - 29171941

AN - SCOPUS:85042359887

VL - 24

SP - 380

EP - 393

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 3

ER -